Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.82
- Piotroski Score 2.00
- Grade Neutral
- Symbol (INMB)
- Company INmune Bio, Inc.
- Price $4.89
- Changes Percentage (2.74%)
- Change $0.13
- Day Low $4.70
- Day High $4.98
- Year High $14.74
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $22.00
- High Stock Price Target $22.00
- Low Stock Price Target $22.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.92
- Trailing P/E Ratio -4.56
- Forward P/E Ratio -4.56
- P/E Growth -4.56
- Net Income $-30,008,000
Income Statement
Quarterly
Annual
Latest News of INMB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...
Raymond Tesi confirmed the Alzheimer's trial data readout is on track for Q2 despite a few extra patients in screening. The recent AbbVie acquisition of Aliada may prompt M&A activity in the Alzheimer...
By Yahoo! Finance | 3 weeks ago -
Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment
INmune Bio's EPS declined by 4.8% over three years, resulting in a 59% loss for shareholders. Shareholders may express discontent at the AGM on July 19, especially regarding CEO compensation....
By Yahoo! Finance | 4 months ago
